DNA-based patient-specific biotechnological medicine
BIOGENERA SpA is a company operating in the biotechnology pharmaceutical sector, specialising in the research and development of new DNA-based patient-specific biotechnological medicines for the treatment of serious pathologies.
Founded in 2008, with its headquarters in Bologna, BIOGENERA SpA is an Innovative Small and Medium-sized Enterprise (ISME) with a multidisciplinary team of researchers and is supported by numerous University partnerships (in particular, the University of Bologna) and other companies of the pharmaceutical sector.
To create new treatments for diseases as yet considered incurable, focusing specifically on paediatric tumors. Thanks to the exclusive MyGeneraTM, platform,
BIOGENERA is capable of rapidly identifying and developing new patient-specific medicines aimed at every therapeutic target made up of single mutated genes, considered causative for a pathology.
MyGeneraTM BIOGENERA is capable of rapidly identifying and developing new patient-specific medicines aimed at every therapeutic target made up of single mutated genes, considered causative for a pathology.
To act at the DNA level developing targeted medicines. Thanks to which it will be possible to revolutionise the cure of serious pathologies, such as tumors, genetic, neurodegenerative, cardiovascular illnesses and, as of today, incurable infectious diseases.
This pioneering approach will allow BIOGENERA SpA to establish itself, in the near future, as the leading company, at the International level, in the research and development of DNA-based patient-specific therapies.
With dedication and commitment focused on responding to the concrete health needs of the individual patient and of society in general.
The passion for research drives us to confront constantly newer challenges and to explore new areas of research for the treatment of incurable pathologies.
A highly qualified, multi-disciplined, motivated and cohesive team that enhances diverse experience, knowledge and professionalism.
Our capacity to integrate the most advanced biotechnologies of the bioinformatic sciences with the frontiers of biomedical and pharmaceutical sciences has opened the doors for a new possible revolution in the field of patient-specific therapies.